Katherine E A Semrau1, Julie Herlihy1, Caroline Grogan2, Kebby Musokotwane3, Kojo Yeboah-Antwi1, Reuben Mbewe4, Bowen Banda5, Chipo Mpamba5, Fern Hamomba5, Portipher Pilingana5, Andisen Zulu5, Pascalina Chanda-Kapata4, Godfrey Biemba6, Donald M Thea1, William B MacLeod1, Jonathon L Simon6, Davidson H Hamer7. 1. Center for Global Health and Development, Boston University School of Public Health, Boston, MA, USA; Department of Global Health, Boston University School of Public Health, Boston, MA, USA. 2. Center for Global Health and Development, Boston University School of Public Health, Boston, MA, USA. 3. Center for Global Health and Development, Boston University School of Public Health, Boston, MA, USA; Ministry of Community Development, Mother and Child Health, Lusaka, Zambia. 4. Ministry of Health, Lusaka, Zambia. 5. ZamCAT Field Office, Zambia Centre for Applied Research and Development (ZCAHRD), Choma, Zambia. 6. Center for Global Health and Development, Boston University School of Public Health, Boston, MA, USA; Department of Global Health, Boston University School of Public Health, Boston, MA, USA; ZCAHRD, Lusaka, Zambia. 7. Center for Global Health and Development, Boston University School of Public Health, Boston, MA, USA; Department of Global Health, Boston University School of Public Health, Boston, MA, USA; ZCAHRD, Lusaka, Zambia; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, USA. Electronic address: dhamer@bu.edu.
Abstract
BACKGROUND:Chlorhexidine umbilical cord washes reduce neonatal mortality in south Asian populations with high neonatal mortality rates and predominantly home-based deliveries. No data exist for sub-Saharan African populations with lower neonatal mortality rates or mostly facility-based deliveries. We compared the effect of chlorhexidine with dry cord care on neonatal mortality rates in Zambia. METHODS: We undertook a cluster-randomised controlled trial in Southern Province, Zambia, with 90 health facility-based clusters. We enrolled women who were in their second or third trimester of pregnancy, aged at least 15 years, and who would remain in the catchment area for follow-up of 28 days post-partum. Newborn babies received clean dry cord care (control) or topical application of 10 mL of a 4% chlorhexidine solution once per day until 3 days after cord drop (intervention), according to cluster assignment. We used stratified, restricted randomisation to divide clusters into urban or two rural groups (located <40 km or ≥40 km to referral facility), and randomly assigned clusters (1:1) to use intervention (n=45) or control treatment (n=45). Sites, participants, and field monitors were aware of their study assignment. The primary outcomes were all-cause neonatal mortality within 28 days post-partum and all-cause neonatal mortality within 28 days post-partum among babies who survived the first 24 h of life. Analysis was by intention to treat. Neonatal mortality rate was compared with generalised estimating equations. This study is registered at ClinicalTrials.gov (NCT01241318). FINDINGS:From Feb 15, 2011, to Jan 30, 2013, we screened 42 356 pregnant women and enrolled 39 679 women (mean 436·2 per cluster [SD 65·3]), who had 37 856 livebirths and 723 stillbirths; 63·8% of deliveries were facility-based. Of livebirths, 18 450 (99·7%) newborn babies in the chlorhexidine group and 19 308 (99·8%) newborn babies in the dry cord care group were followed up to day 28 or death. 16 660 (90·0%) infants in the chlorhexidine group had chlorhexidine applied within 24 h of birth. We found no significant difference in neonatal mortality rate between the chlorhexidine group (15·2 deaths per 1000 livebirths) and the dry cord care group (13·6 deaths per 1000 livebirths; risk ratio [RR] 1·12, 95% CI 0·88-1·44). Eliminating day 0 deaths yielded similar findings (RR 1·12, 95% CI 0·86-1·47). INTERPRETATION: Despite substantial reductions previously reported in south Asia, chlorhexidine cord applications did not significantly reduce neonatal mortality rates in Zambia. Chlorhexidine cord applications do not seem to provide clear benefits for newborn babies in settings with predominantly facility-based deliveries and lower (<30 deaths per 1000 livebirths) neonatal mortality rates. FUNDING: Bill & Melinda Gates Foundation.
RCT Entities:
BACKGROUND:Chlorhexidine umbilical cord washes reduce neonatal mortality in south Asian populations with high neonatal mortality rates and predominantly home-based deliveries. No data exist for sub-Saharan African populations with lower neonatal mortality rates or mostly facility-based deliveries. We compared the effect of chlorhexidine with dry cord care on neonatal mortality rates in Zambia. METHODS: We undertook a cluster-randomised controlled trial in Southern Province, Zambia, with 90 health facility-based clusters. We enrolled women who were in their second or third trimester of pregnancy, aged at least 15 years, and who would remain in the catchment area for follow-up of 28 days post-partum. Newborn babies received clean dry cord care (control) or topical application of 10 mL of a 4% chlorhexidine solution once per day until 3 days after cord drop (intervention), according to cluster assignment. We used stratified, restricted randomisation to divide clusters into urban or two rural groups (located <40 km or ≥40 km to referral facility), and randomly assigned clusters (1:1) to use intervention (n=45) or control treatment (n=45). Sites, participants, and field monitors were aware of their study assignment. The primary outcomes were all-cause neonatal mortality within 28 days post-partum and all-cause neonatal mortality within 28 days post-partum among babies who survived the first 24 h of life. Analysis was by intention to treat. Neonatal mortality rate was compared with generalised estimating equations. This study is registered at ClinicalTrials.gov (NCT01241318). FINDINGS: From Feb 15, 2011, to Jan 30, 2013, we screened 42 356 pregnant women and enrolled 39 679 women (mean 436·2 per cluster [SD 65·3]), who had 37 856 livebirths and 723 stillbirths; 63·8% of deliveries were facility-based. Of livebirths, 18 450 (99·7%) newborn babies in the chlorhexidine group and 19 308 (99·8%) newborn babies in the dry cord care group were followed up to day 28 or death. 16 660 (90·0%) infants in the chlorhexidine group had chlorhexidine applied within 24 h of birth. We found no significant difference in neonatal mortality rate between the chlorhexidine group (15·2 deaths per 1000 livebirths) and the dry cord care group (13·6 deaths per 1000 livebirths; risk ratio [RR] 1·12, 95% CI 0·88-1·44). Eliminating day 0 deaths yielded similar findings (RR 1·12, 95% CI 0·86-1·47). INTERPRETATION: Despite substantial reductions previously reported in south Asia, chlorhexidine cord applications did not significantly reduce neonatal mortality rates in Zambia. Chlorhexidine cord applications do not seem to provide clear benefits for newborn babies in settings with predominantly facility-based deliveries and lower (<30 deaths per 1000 livebirths) neonatal mortality rates. FUNDING: Bill & Melinda Gates Foundation.
Authors: Luke C Mullany; Shams El Arifeen; Subarna K Khatry; Joanne Katz; Rashed Shah; Abdullah H Baqui; James M Tielsch Journal: Pediatr Infect Dis J Date: 2017-10 Impact factor: 2.129
Authors: Katherine L Anders; Zoe Cutcher; Immo Kleinschmidt; Christl A Donnelly; Neil M Ferguson; Citra Indriani; Peter A Ryan; Scott L O'Neill; Nicholas P Jewell; Cameron P Simmons Journal: Am J Epidemiol Date: 2018-09-01 Impact factor: 4.897
Authors: Victoria Nankabirwa; Thorkild Tylleskär; Josephine Tumuhamye; James K Tumwine; Grace Ndeezi; José C Martines; Halvor Sommerfelt Journal: Trials Date: 2017-07-12 Impact factor: 2.279
Authors: Angela Muriuki; Francis Obare; Bill Ayieko; Dennis Matanda; Kenneth Sisimwo; Brian Mdawida Journal: BMC Health Serv Res Date: 2017-04-26 Impact factor: 2.655
Authors: Elizabeth G Henry; Katherine Semrau; Davidson H Hamer; Taryn Vian; Mary Nambao; Kaluba Mataka; Nancy A Scott Journal: Reprod Health Date: 2017-05-30 Impact factor: 3.223
Authors: Peter C Rockers; Arianna Zanolini; Bowen Banda; Mwaba Moono Chipili; Robert C Hughes; Davidson H Hamer; Günther Fink Journal: PLoS Med Date: 2018-04-24 Impact factor: 11.069
Authors: Angela Dramowski; Sheylyn Pillay; Adrie Bekker; Ilhaam Abrahams; Mark F Cotton; Susan E Coffin; Andrew C Whitelaw Journal: EClinicalMedicine Date: 2021-06-18